Question

Difficulty: HardUrologic Surgery

A 68-year-old man comes to the urology clinic to discuss the results of a recent procedure. He initially presented with a 22-month history of painless, intermittent gross hematuria. His past medical history is notable for hypertension, hyperlipidemia, and a 4040-pack-year smoking history. Physical examination is unremarkable. Last week, he underwent cystoscopy which revealed a 44-cm solid, sessile tumor on the posterior wall of the bladder. A transurethral resection of the bladder tumor (TURBT) was performed. The pathology report from the resected tissue demonstrates high-grade urothelial carcinoma with extensive invasion into the muscularis propria (detrusor muscle). A subsequent staging computed tomography (CT) scan of the chest, abdomen, and pelvis shows no evidence of pelvic lymphadenopathy or distant metastasis. Which of the following is the most appropriate next step in the management of this patient?

  1. Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomyAnswer
  2. B
    Induction course of intravesical Bacillus Calmette-Guérin (BCG) therapy
  3. C
    Repeat transurethral resection of the bladder tumor (TURBT) in 4 weeks
  4. D
    Initiation of prophylactic broad-spectrum antibiotics and surveillance cystoscopy
  5. E
    Primary external beam radiation therapy (EBRT) as monotherapy

Answer

The most appropriate next step is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy.
The patient has localized muscle-invasive bladder cancer (MIBC), defined by tumor invasion into the muscularis propria (detrusor muscle). The gold standard treatment for surgically fit patients with MIBC is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. This multimodal approach offers the best chance for a cure, as the chemotherapy treats early micrometastatic disease and the cystectomy removes the primary local tumor.

Step-by-Step Solution

1
Analyze the pathology report from the TURBT.
The tumor is a high-grade urothelial carcinoma that invades the muscularis propria (detrusor muscle).
Identifying the depth of invasion is the critical factor in staging bladder cancer.
2
Determine the clinical stage based on pathology and imaging.
Detrusor muscle invasion indicates at least Stage T2 (muscle-invasive) disease. Negative CT imaging confirms there is no lymph node involvement (N0) or distant metastasis (M0).
Clinical staging dictates the definitive treatment pathway.
3
Identify the standard of care for localized muscle-invasive bladder cancer (MIBC).
The standard of care is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with urinary diversion.
Neoadjuvant chemotherapy provides a well-documented overall survival benefit by eradicating micrometastatic disease prior to surgical removal of the primary tumor.

Key Concept

The presence of muscularis propria (detrusor muscle) invasion on a bladder tumor biopsy upgrades the disease from non-muscle-invasive (managed with TURBT and intravesical therapy) to muscle-invasive, which requires definitive radical cystectomy, typically preceded by neoadjuvant chemotherapy.
Rate this question